Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 1:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Active Metabolic Product 1 Clear all
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Assessing the Impact of Contraceptives on Bone Health Using 41Ca

NCT02367846
View directory record Official record
Conditions
Other Disorders of Bone Development and Growth
Interventions
Combined Oral Contraceptive (COC), Contraceptive Vaginal Ring (CVR)
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 29, 2026, 1:40 PM EDT
Terminated Phase 2 Interventional Results available

Pembro+Chemo in Brain Mets

NCT04964960
View directory record Official record
Conditions
Lung Cancer, Lung Cancer Metastatic, Brain Cancer, Cancer
Interventions
Pembrolizumab, Nab paclitaxel, Paclitaxel, Pemetrexed, Carboplatin
Drug
Lead sponsor
John L. Villano, MD, PhD
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 29, 2026, 1:40 PM EDT
Completed Phase 2 Interventional

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

NCT04251182
View directory record Official record
Conditions
Alzheimer Disease
Interventions
15mg T3D-959, 30 mg T3D-959, 45 mg T3D-959, Placebos
Drug
Lead sponsor
T3D Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 29, 2026, 1:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

NCT02367833
View directory record Official record
Conditions
Bone; Disorder, Development and Growth
Interventions
Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Sep 29, 2026, 1:40 PM EDT
Completed Not applicable Interventional

Treatment of Low Metabolic Rate Following Bariatric Surgery

NCT01596907
View directory record Official record
Conditions
Morbid Obesity
Interventions
Ephedrine sulfate with caffeine, cellulose
Drug
Lead sponsor
Oregon Weight Loss Surgery, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Beaverton, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 29, 2026, 1:40 PM EDT
Completed Phase 2 Interventional

R33: Levetiracetam in Early Psychosis

NCT04317807
View directory record Official record
Conditions
Early Psychosis
Interventions
Levetiracetam Pill, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 29, 2026, 1:40 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Radicle HealthTM VIP: A Study Assessing the Impact of Health and Wellness Products on Metabolic Health and Related Health Outcomes

NCT07819110
View directory record Official record
Conditions
Metabolic Health
Interventions
Placebo Metabolic Control 1, Active Metabolic Product 1
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 29, 2026, 1:40 PM EDT
Not listed Phase 4 Interventional

Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

NCT04027023
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes mellitus Type 2 De-escalation treatment (DET)
Drug
Lead sponsor
Sciema UG
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 29, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort

NCT02286635
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Deflazacort and rifampin, Deflazacort and Clarithromycin
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 29, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer

NCT03449901
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
pegylated arginine deiminase, Gemcitabine, Docetaxel, Tumor biopsy, Research blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
10 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Palo Alto, California • Santa Monica, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 29, 2026, 1:40 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Precision Functional Brain Mapping in Psilocybin

NCT04501653
View directory record Official record
Conditions
Psilocybin
Interventions
Psilocybin, Methylphenidate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 29, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics

NCT02286622
View directory record Official record
Conditions
Renal Impairment
Interventions
Deflazacort
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 29, 2026, 1:40 PM EDT
Completed Phase 1 Interventional

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

NCT01273168
View directory record Official record
Conditions
Hormone Receptor-Positive Breast, Gynecologic, Desmoid, Hormone Receptor-Positive Neoplasms
Interventions
Z-Endoxifen
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 29, 2026, 1:40 PM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 29, 2026, 1:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CYP2B6 Genetics and Drug Interactions in Healthy Volunteers

NCT02401256
View directory record Official record
Conditions
Healthy
Interventions
Efavirenz, Bupropion, Rosuvastatin, Montelukast
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 29, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency

NCT01007071
View directory record Official record
Conditions
Hypopituitarism
Interventions
Human Growth Hormone (1-134), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 29, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of PDE5 Inhibition on Adipose Metabolism in Humans

NCT04684589
View directory record Official record
Conditions
Obesity
Interventions
Tadalafil 20 MG, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
19 Years to 50 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 29, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

Propranolol for Sleep Apnea Therapy

NCT03049306
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Propranolol Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 29, 2026, 1:40 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Fibrosis Lessens After Metabolic Surgery

NCT06374875
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
Interventions
Metabolic surgery, Incretin-Based Therapy
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
4
States / cities
Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 29, 2026, 1:40 PM EDT
Completed Phase 1 Interventional

VRS-317 in Adult Subjects With Growth Hormone Deficiency

NCT01359488
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
VRS-317
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2012 · Synced Sep 29, 2026, 1:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Sildenafil Citrate on Insulin Resistance in African American

NCT01334554
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 29, 2026, 1:40 PM EDT
Terminated Phase 1Phase 2 Interventional

First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations

NCT04409145
View directory record Official record
Conditions
Venous Malformation, Lymphatic Malformation, Venolymphatic Malformation
Interventions
VT30
Drug
Lead sponsor
Venthera, Inc., a BridgeBio company
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Sep 29, 2026, 1:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance

NCT04074668
View directory record Official record
Conditions
Diabetic Kidney Disease, Type 1 Diabetes, Diabetes, Diabetes Mellitus, Diabetes Complications, Diabetic Nephropathies, Type1diabetes, Diabetes, Autoimmune, Autoimmune Diabetes, Juvenile Diabetes, Type 1 Diabetes Mellitus
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 milligrams/milliliter (mg/ml), PET/CT Scan, Renal Biopsy
Drug · Radiation · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 30 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 29, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

High-fat Meal Challenge in Pediatrics

NCT05230433
View directory record Official record
Conditions
Pediatric Obesity, Insulin Resistance
Interventions
High-fat Challenge
Dietary Supplement
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
8 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 29, 2026, 1:40 PM EDT